Make your own free website on Tripod.com

Welcome to Dr. Hamid Sanatinia's Virtual Headquarters
Antiemetics

Home

Should we treat or not???
Performace Status
Antiemetics
Growth Factors
Calculations
Chemo Precautions
TOXICITY CRITERIA
Antidepressants
Chemoprotection
MESNA
Dexrazoxane
Radioprotectants
Hypercalcemia of malignancy
Mucositis
Neutropenic Fever
Palliative Care
Radiation Oncology
<<<<<<<<<>>>>>>>>>
ALL
AML
Anal
Bladder Cancer
Brain Cancer
Breast (risk category)
Breast (adjuvant)
Breast (metastatic)
Breast (Xeloda)
Breast (hormonal)
Breast Cancer Genetics
Carcinoid
CLL
CML
COLON CANCER
Endometrial
Esophagous
Gastric
Gestational Trophoblastic Disease
Germ Cell (Ovary)
Hairy Cell Leukemia
Head/Neck
Head/Neck: ChemoRT abstracts
Head/Neck: Larynx
Head/Neck:Nasopharyngeal
Hodgkins
Islet Cell Tumors
Kidney
Liver
LUNG, NSC
Stage III Unresectable NSC Lung Cancer
Lung, SC
Lymphoma, Aggressive
Lymphoma, AIDS
Lymphoma, Burkitts
Lymphoma, CNS
Lymphoma, Cutaneous
Lymphoma, Indolent
Lymphoma, MALT
Lymphoma, Mantle cell
Lymphoma, Mediastinal B-Cell
Lymphoma, Refractory NHL
Melanoma
Mesothelioma
Multiple Myeloma
MDS
NHL
Ovarian
Pancreas
Prostate
Prostate (Hormonal)
Rectal Cancer
Sarcoma
Sarcoma, Ewing's
Sarcoma, Osteogenic
Skeletal Metastasis
Testicular Cancer
Thymoma
Thyroid Cancer
Waldenstrom's
Unknown Primary
<<<<<<<<<>>>>>>>>>
Molecular Genetics
Oncogenes, the list!
Immunoperoxidase stains
Tumor Markers
Bleomycin
Cisplatin
Etoposide
Ifosfamide
Methotrexate
Temazolamide
Mechanism of Action
Dose Modifications (Renal)
Dose Modifications (hepatic)
MDR

Serotonin Receptor Antagonists
Dopamine Receptor Antagonists
Corticosteriods
Other Agents

Serotonin Receptor Antagonists:
Dolasetron (Anzemet) 100 mg PO X 1 or 100 mg (1.8 mg/kg) IV
Granisetron (Kytril) 1 mg PO X 1 or 1 mg (0.01 mg/kg) IV
Ondansetron (Zofran) 16-24 mg PO X 1 or 8 mg po BID or 8 mg (0.15 mg/Kg) IV
--------------------------------------------------------------

Corticosteroids:
Dexamethasone 20 mg po/IV X1

--------------------------------------------------------------

Other Agents:
Droperidol (Inapsine) 1.25-2.5 mg IV or 2.5-10 mg IM
Metoclopramide (Reglan) 2-3 mg/kg Q 2hours IV/PO
Haloperidol 1-2 mg PO/IV Q 4-6 hours
Dronabinol 5 mg/m2 Q 4hours PO
Prochlorperzine (Compazine) 10-20 mg IV Q2-3 hours
Promethazine (Phenergan) 12.5-25 mg PO/IM/PR Q4-6 hours
Olanzapine (Zyrpexa) 10-15 mg po QD
Lorazepam 0.5-2.0 mg PO/SL/IV

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
DELAYED EMESIS REGIMEN:
In all patients receiving CISPLATIN, a corticosteroid + metoclopramide or a 5-HT3 antagonist is recommended for the prevention of delayed emesis.

Among patients receiving CYCLOPHOSPHAMIDE, ANTHRACYCLINES, CARBOPLATIN, or combinations of these agents, the incidence of delayed emesis varied from 20% to 30% in patients not given prophylactic antiemetics for delayed emesis. Use of a corticosteroid as part of the acute emesis regimen was associated with a lower incidence of delayed emesis. A delayed emesis regimen may be given with this degree of risk, but data are lacking concerning efficacy & specific regimen choices.
<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<

Emetic Potential:
--VERY HIGH--
Cisplatin
-----HIGH-----
Carboplatin
Carmustine
Cyclophosphamide
Cytarabine
Dacarbazine
Doxorubicin
Epirubicin
Hexamethylmelamine
Idarubicin
Ifosfamide
Mechlorethamine
Mitoxantrone
Procarbazine
Streptozocin
--INTERMEDIATE--
Docetaxel
Etoposide
Fluorouracil
Irinotecan
Gemcitibine
Methotrexate (>50 mg/m2)
Mitomycin
Paclitaxel
----LOW----
Belomycin
Busulfan
Chlorambucil
Fludarabine
Hydroxyurea
Methotrexate (<50 mg/m2)
Melphalan
Thioguanine
Vinblastine
Vincristine
Vinorelbine